Skip to main navigation Skip to search Skip to main content

Costs of dacomitinib versus placebo in pretreated unselected patients (pts) with advanced NSCLC: CCTG BR.26

  • S. Karim
  • , K. Ding
  • , P. Bradbury
  • , P. Ellis
  • , N. Mittman
  • , X. Xiaoqun Sun
  • , M. Millward
  • , G. Liu
  • , S. Sun
  • , M. R. Stockler
  • , V. Cohen
  • , N. Blais
  • , R. Sangha
  • , M. Boyer
  • , R. Sasidharan
  • , C. Lee
  • , F. A. Shepherd
  • , G. Goss
  • , L. Seymour
  • , N. B. Leighl

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

Original languageEnglish
Number of pages1
JournalAnnals of Oncology
Volume28
Publication statusPublished - Sept 2017
Externally publishedYes
Event42nd European-Society-for-Medical-Oncology Congress (ESMO) - Madrid, Spain
Duration: 8 Sept 201712 Sept 2017

Cite this